Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone

BACKGROUND: Combination therapy with an inhaled corticosteroid (ICS) and long-acting β(2) agonist (LABA) is recommended for patients with asthma symptomatic on ICS alone. However, there is ongoing debate regarding the risk-benefit ratio of using LABA in asthma. OBJECTIVE: To evaluate the effect of t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Bateman, Eric D, O'Byrne, Paul M, Busse, William W, Lötvall, Jan, Bleecker, Eugene R, Andersen, Leslie, Jacques, Loretta, Frith, Lucy, Lim, Jessica, Woodcock, Ashley
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2014
Matèries:
Asthma
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3963539/
https://ncbi.nlm.nih.gov/pubmed/24253831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2013-203600
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars